This site provides research and comparisons, not medical advice. Consult your pediatrician before changing your baby's formula.
EU Regulation 2016/127 Annex II is the single most important document for understanding why European infant formulas have specific compositional patterns. The Annex is a structured table listing every nutrient that EU-marketed infant formulas must contain, with mandatory minimum and maximum ranges. The table is where "EU formulas have higher DHA," "EU formulas mandate lactose predominance," and "EU formulas have stricter iron limits" actually come from in regulatory text, not marketing claims.
EU 2016/127 Annex II specifies mandatory nutrient ranges for every infant formula sold in the EU. Distinct from FDA 21 CFR 107 in several ways: EU mandates DHA at 20-50 mg/100 kcal (FDA only permits, doesn't mandate), EU mandates lactose predominance in Stage 1 (FDA permits maltodextrin/corn-syrup-solids), EU has tighter iron ranges, EU restricts certain protein sources in Stage 1. Annex II is updated periodically by EFSA scientific opinion; the last major update was February 2020 when the DHA mandate took effect.
What Annex II covers
Annex II of EU Regulation 2016/127 specifies mandatory composition for infant formula (Stage 1, 0-6 months) and follow-on formula (Stage 2, 6-12 months), based on the EFSA Scientific Opinion on essential composition of infant and follow-on formulas. The structure:
Energy density: 60-70 kcal per 100 ml prepared formula. Most formulas target ~67 kcal/100 ml, matching mature breast milk.
Macronutrients:
- Protein: 1.8-2.5 g per 100 kcal (Stage 1), 1.6-2.5 g per 100 kcal (Stage 2). Protein-source restrictions specify which proteins are permitted (cow milk, goat milk, soy isolate, hydrolyzed proteins) and amino acid composition requirements.
- Fat: 4.4-6.0 g per 100 kcal. Specific fatty acid ratios required including linoleic acid, alpha-linolenic acid, and the mandatory DHA range.
- Carbohydrate: 9-14 g per 100 kcal. Lactose must predominate in Stage 1 formulas — this is the regulatory basis for EU formulas being lactose-only or lactose-primary by mandate.
The DHA mandate (since February 2020): 20-50 mg of DHA per 100 kcal in all infant formulas. This was added to Annex II following EFSA's scientific opinion on DHA dietary reference values for infants. It's the single biggest distinction between EU and US infant formulas — DHA is mandatory in every EU formula, optional in US formulas (though most major US brands include it voluntarily).
Vitamins: Specific min-max ranges for vitamins A, D, E, K, C, thiamin, riboflavin, niacin, B6, B12, pantothenic acid, biotin, and folate. Annex II requires Metafolin (5-methyltetrahydrofolate calcium) or folic acid in specific dose ranges.
Minerals: Specific min-max ranges for sodium, potassium, chloride, calcium, phosphorus, magnesium, iron, zinc, copper, iodine, selenium, manganese. Iron range (0.45-1.3 mg per 100 kcal) is tighter than FDA's permitted range.
Optional ingredients (Annex II Section 5): Ingredients that manufacturers may add but aren't required. Includes prebiotic GOS
- FOS at specific ratios, certain probiotic strains, choline, inositol, taurine, L-carnitine, nucleotides. The optional-ingredient list has historically driven product differentiation across EU brands — HiPP's Combiotik probiotic is an Annex II optional addition.
How Annex II differs from FDA 21 CFR 107
| Axis | EU Annex II | FDA 21 CFR 107 |
|---|---|---|
| DHA | Mandatory 20-50 mg/100 kcal | Permitted, not required |
| Lactose predominance | Mandatory in Stage 1 | Permitted; maltodextrin/corn-syrup-solids allowed |
| Iron range | 0.45-1.3 mg/100 kcal (Stage 1) | 0.15-3.0 mg/100 kcal |
| Protein range | 1.8-2.5 g/100 kcal (Stage 1) | 1.8-4.5 g/100 kcal |
| Probiotic strains | Permitted via Annex II Section 5 | Permitted (no equivalent structured list) |
| GOS+FOS ratio | Permitted at specific ratios | Permitted |
| Folate form | Metafolin or folic acid permitted | Folic acid (Metafolin uncommon) |
| Composition update mechanism | EFSA scientific opinion → regulatory amendment | FDA petition + rule-making |
Two implications worth tracing:
Implication 1 — EU formulas are more compositionally constrained. A US formula can shift its carbohydrate base to corn syrup solids without violating FDA 21 CFR 107; an EU formula with corn syrup as primary carbohydrate would violate Annex II's lactose-predominance mandate. This regulatory difference creates the structural EU vs US ingredient gap that drives many parent preferences for EU imports.
Implication 2 — EU formulas update faster on emerging science. EFSA scientific opinions trigger Annex II amendments. The DHA mandate was added in 2016 (effective 2020) following EFSA's 2014 opinion on DHA dietary reference values. FDA's equivalent process (rule-making) is slower. The DHA mandate is currently the largest single advantage EU formulas have over US formulas — and it's a regulatory distinction, not a marketing one.
Why Annex II keeps EU formulas relatively stable
Manufacturer reformulation flexibility is constrained by Annex II ranges. A HiPP, Holle, Kendamil EU, or Loulouka can't dramatically change their composition without staying within Annex II ranges. This is why EU formulas reformulate less frequently than US formulas — the regulatory bands are tighter, leaving less room for silent reformulation.
For parents importing EU formulas, this is a meaningful stability signal. The HiPP Dutch Stage 1 you bought in 2024 has similar composition to HiPP Dutch Stage 1 in 2026, because Annex II limits the reformulation window. US formulas like Similac and Enfamil can reformulate more freely (within FDA 21 CFR 107) and historically have done so more often.
How Annex II gets updated
Per Article 11 of EU Regulation 2016/127, Annex II amendments follow a structured process:
- EFSA scientific opinion. EFSA reviews emerging science (e.g., new DHA evidence, new prebiotic safety data, updated nutrient reference values).
- Commission delegated act. European Commission issues a delegated regulation amending the Annex.
- Transition period. Manufacturers get a multi-year window (typically 3-5 years) to reformulate to the new requirements.
- Effective date. Old formulas can no longer be marketed in the EU.
The DHA mandate followed this process: EFSA opinion 2014, regulation 2016, effective February 2020 (4-year transition). Future updates (potentially expanding probiotic strains, refining HMO permissions, or restricting certain processing aids) follow the same path.